• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Edge Higher; General Motors Posts Upbeat Earnings

    7/23/24 10:15:13 AM ET
    $ADIL
    $ATPC
    $AZTR
    $GM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ADIL alert in real time by email

    U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday.

    Following the market opening Tuesday, the Dow traded up 0.01% to 40,421.01 while the NASDAQ rose 0.19% to 18,041.10. The S&P 500 also rose, gaining, 0.18% to 5,574.56.

    Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report

    Leading and Lagging Sectors

    Consumer discretionary shares jumped by 0.8% on Tuesday.

    In trading on Tuesday, utilities shares fell by 0.5%.

    Top Headline

    General Motors Company (NYSE:GM) reported better-than-expected second-quarter earnings and raised its guidance.

    General Motors reported a fiscal second-quarter 2024 sales growth of 7.2% year-on-year to $47.97 billion, beating the analyst consensus estimate of $45.30 billion. The adjusted EPS of $3.06 beat the analyst consensus estimate of $2.72.

    Equities Trading UP
                           

    • Azitra, Inc. (NYSE:AZTR) shares shot up 517% to $10.00 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.
    • Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) got a boost, surging 158% to $2.75 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.
    • Agape ATP Corporation (NASDAQ:ATPC) shares were also up, gaining 65% to $0.2356.

    Equities Trading DOWN

    • Jaguar Health, Inc. (NASDAQ:JAGX) shares dropped 66% to $1.4203 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.
    • Shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) were down 62% to $0.3007 after the company announced a proposed public offering.
    • Exicure, Inc. (NASDAQ:XCUR) was down, falling 30% to $0.3523.

    Also Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields

    Commodities

    In commodity news, oil traded down 0.3% to $78.14 while gold traded up 0.7% at $2,410.80.

    Silver traded down 0.1% to $29.295 on Tuesday, while copper fell 0.6% to $4.1740.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 climbed 0.6%, Germany's DAX gained 1.3% and France's CAC 40 climbed 0.4%. Spain's IBEX 35 Index rose 0.7%, while London's FTSE 100 rose 0.4%.

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&P BSE Sensex declining 0.09%.

    The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People’s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.

    Economics

    • The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.
    • Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.

    Now Read This:

    • This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ATPC
    $AZTR
    $GM

    CompanyDatePrice TargetRatingAnalyst
    General Motors Company
    $GM
    1/29/2026$98.00Hold → Buy
    DZ Bank
    General Motors Company
    $GM
    1/8/2026$98.00Neutral → Overweight
    Piper Sandler
    General Motors Company
    $GM
    12/8/2025$90.00Equal-Weight → Overweight
    Morgan Stanley
    General Motors Company
    $GM
    9/24/2025$81.00Neutral → Buy
    UBS
    General Motors Company
    $GM
    9/12/2025$73.00Equal Weight → Overweight
    Barclays
    General Motors Company
    $GM
    7/21/2025$65.00Buy
    The Benchmark Company
    General Motors Company
    $GM
    4/23/2025$62.00Buy
    Citigroup
    General Motors Company
    $GM
    4/15/2025$40.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $ADIL
    $ATPC
    $AZTR
    $GM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CADILLAC FORMULA 1® TEAM REVEALS HISTORIC FIRST LIVERY

    INDIANAPOLIS and SILVERSTONE, U.K., Feb. 8, 2026 /PRNewswire/ -- The Cadillac Formula 1® Team today unveiled the livery of its maiden Formula 1® challenger, marking a defining milestone in the team's journey to the world's most elite motorsport championship. The striking white and black scheme will be used by the American squad throughout 2026, when it makes its much-anticipated debut in Formula 1® as the sport's 11th team. The livery was unveiled to a global audience through a national TV advertising spot during Super Bowl LX at Levi's Stadium in Santa Clara, California. With

    2/8/26 10:30:00 PM ET
    $GM
    Auto Manufacturing
    Industrials

    Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

    BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the "SEC") on January 2, 2026 (the "Special Meeting Proxy Statement") becau

    2/6/26 4:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

    BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first exp

    2/5/26 8:04:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATPC
    $AZTR
    $GM
    SEC Filings

    View All

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    2/10/26 4:25:41 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    2/6/26 4:17:06 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    2/6/26 4:15:22 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATPC
    $AZTR
    $GM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair & CEO Barra Mary T converted options into 42,730 shares, covered exercise/tax liability with 245,123 shares and was granted 521,778 shares, increasing direct ownership by 70% to 775,816 units (SEC Form 4)

    4 - General Motors Co (0001467858) (Issuer)

    2/10/26 4:10:30 PM ET
    $GM
    Auto Manufacturing
    Industrials

    President Reuss Mark L converted options into 30,596 shares, covered exercise/tax liability with 175,562 shares and was granted 373,607 shares, increasing direct ownership by 200% to 342,959 units (SEC Form 4)

    4 - General Motors Co (0001467858) (Issuer)

    2/10/26 4:09:11 PM ET
    $GM
    Auto Manufacturing
    Industrials

    Executive Vice President Harvey Rory converted options into 15,531 shares, covered exercise/tax liability with 83,455 shares and was granted 176,542 shares, increasing direct ownership by 624% to 126,013 units (SEC Form 4)

    4 - General Motors Co (0001467858) (Issuer)

    2/10/26 4:06:47 PM ET
    $GM
    Auto Manufacturing
    Industrials

    $ADIL
    $ATPC
    $AZTR
    $GM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    3/26/25 5:41:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kelly Alfred F Jr bought $607,920 worth of shares (12,000 units at $50.66), increasing direct ownership by 700% to 13,714 units (SEC Form 4)

    4 - General Motors Co (0001467858) (Issuer)

    1/30/25 5:20:55 PM ET
    $GM
    Auto Manufacturing
    Industrials

    Large owner Dgp Co., Ltd. bought $711,669 worth of shares (237,223 units at $3.00), increasing direct ownership by 39% to 849,223 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    9/16/24 9:41:12 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATPC
    $AZTR
    $GM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    General Motors upgraded by DZ Bank with a new price target

    DZ Bank upgraded General Motors from Hold to Buy and set a new price target of $98.00

    1/29/26 6:58:08 AM ET
    $GM
    Auto Manufacturing
    Industrials

    General Motors upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded General Motors from Neutral to Overweight and set a new price target of $98.00

    1/8/26 8:11:20 AM ET
    $GM
    Auto Manufacturing
    Industrials

    General Motors upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded General Motors from Equal-Weight to Overweight and set a new price target of $90.00

    12/8/25 8:14:17 AM ET
    $GM
    Auto Manufacturing
    Industrials

    $ADIL
    $ATPC
    $AZTR
    $GM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc

    SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

    11/14/24 3:44:01 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATPC
    $AZTR
    $GM
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mativ Appoints Scott Minder as New Chief Financial Officer

    Minder Brings 30+ Years of Financial Leadership and Proven Track-Record of Reducing Leverage, Generating Cash Flow, and Driving Profitability in Public and Private Companies Mativ Holdings, Inc. ("Mativ" or the "Company") (NYSE:MATV) today announced the appointment of Scott Minder as Chief Financial Officer, effective January 1, 2026. Mr. Minder will succeed Greg Weitzel, who will remain with the Company through December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216240784/en/Scott Minder, Chief Financial Officer, Mativ Minder is an accomplished financial executive with more than 30 years of experience leading f

    12/16/25 4:16:00 PM ET
    $ATI
    $GM
    $HY
    Steel/Iron Ore
    Industrials
    Auto Manufacturing
    Construction/Ag Equipment/Trucks

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATPC
    $AZTR
    $GM
    Financials

    Live finance-specific insights

    View All

    GM releases 2025 financial results and 2026 guidance; Board declares dividend at 20% higher quarterly rate, and approves new $6.0 billion share repurchase authorization

    DETROIT, Jan. 27, 2026 /PRNewswire/ -- General Motors (NYSE:GM) today reported full-year 2025 net income attributable to stockholders of $2.7 billion and EBIT-adjusted of $12.7 billion. Fourth-quarter 2025 net income attributable to stockholders was a loss of $3.3 billion and EBIT-adjusted was $2.8 billion. Fourth-quarter net income was reduced by more than $7.2 billion in special charges driven primarily by a realignment of electric vehicle capacity and investments to adjust to expected declines in consumer demand for EVs, and in response to U.S. Government policy changes including the termination of consumer incentives and the reduction in the stringency of emissions regulations. The char

    1/27/26 6:30:00 AM ET
    $GM
    Auto Manufacturing
    Industrials

    Exicure, Inc. Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen

    11/7/25 4:00:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GM releases 2025 third-quarter results

    DETROIT, Oct. 21, 2025 /PRNewswire/ -- General Motors (NYSE:GM) today reported third-quarter 2025 revenue of $48.6 billion, net income attributable to stockholders of $1.3 billion, and EBIT-adjusted of $3.4 billion. GM is also updating its 2025 full-year earnings guidance: Updated 2025 guidance Previous 2025 guidance Net income attributable to stockholders $7.7 billion - $8.3 billion $7.7 billion - $9.5 billion EBIT-adjusted $12.0 billion - $13.0 billion $10.0 billion - $12.5 billion Automotive operating cash flow $19.2 billion - $21.2 billion $17.0 billion - $20.5 billion Adjusted automotive free cash flow $10.0 billion - $11.0 billion $7.5 billion - $10.0 billion EPS-diluted $8.30 - $9.05

    10/21/25 6:30:00 AM ET
    $GM
    Auto Manufacturing
    Industrials